Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Reduced by Atria Investments Inc

Atria Investments Inc lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 19.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,495 shares of the company’s stock after selling 1,307 shares during the quarter. Atria Investments Inc’s holdings in Neurocrine Biosciences were worth $633,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. boosted its position in Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after purchasing an additional 504,400 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after buying an additional 228,444 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after buying an additional 220,598 shares in the last quarter. Iron Triangle Partners LP acquired a new position in Neurocrine Biosciences in the first quarter worth approximately $30,342,000. Finally, Renaissance Technologies LLC raised its position in Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the topic of a number of recent research reports. BMO Capital Markets cut their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a report on Thursday, October 17th. Jefferies Financial Group boosted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Oppenheimer upped their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Up 1.3 %

Shares of NASDAQ:NBIX opened at $119.13 on Wednesday. The firm has a market cap of $12.06 billion, a price-to-earnings ratio of 31.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $108.14 and a 12 month high of $157.98. The company’s fifty day simple moving average is $118.44 and its 200 day simple moving average is $132.40.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.